Biosimilars should slash up to 50% off reference product prices, says Oncobiologics' Pankaj Mohan

The companies aiming to take advantage of patent expiries of some of the world’s best-selling biologics – be they the Sandoz unit of Swiss pharma giant Novartis (NOVN: VX), US biotech majors Amgen (Nasdaq: AMGN) and Biogen (Nasdaq: BIIB) or others of similar ilk – are some of the industry’s big players.

Oncobiologics (Nasdaq: ONS), a US-based company that recently completed its initial public offering, certainly does not fit that mould.

However, just five years after its formation, it already has its own platform for developing, manufacturing and commercializing biosimilars, including a version of the world’s biggest-selling drug, AbbVie's (NYSE: ABBV) Humira (adalimumab), which will soon enter the Phase III stage, and others in less crowded but highly attractive markets.